A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men
暂无分享,去创建一个
Z. Szallasi | M. Loda | I. Csabai | T. Werner | Qiyuan Li | D. Takeda | S. Srivastava | M. Freedman | M. Seifert | I. Sesterhenn | Hua Li | S. Srivastava | M. Scherf | C. Dalgard | B. Klocke | Yongmei Chen | G. Petrovics | D. Ribli | D. Mcleod | K. Grote | J. Kagan | T. Gaiser | Joseph C. Cheng | A. Dobi | L. Ravindranath | Shyh-Han Tan | I. Kohaar | R. Ebner | D. Young | Shilpa Katta | Shimin Zhang | Huaying Zou | K. Ying | Tanja Stümpel
[1] Faraz Hach,et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer , 2015, Nature Genetics.
[2] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[3] Mingming Jia,et al. COSMIC: exploring the world's knowledge of somatic mutations in human cancer , 2014, Nucleic Acids Res..
[4] A. Jemal,et al. Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.
[5] C. Liao,et al. Cells of origin in the embryonic nerve roots for NF1-associated plexiform neurofibroma. , 2014, Cancer cell.
[6] S. Srivastava,et al. Predominance of ERG-negative high-grade prostate cancers in African American men. , 2014, Molecular and clinical oncology.
[7] M. Rubin,et al. Evidence for Molecular Differences in Prostate Cancer between African American and Caucasian Men , 2014, Clinical Cancer Research.
[8] Huiqing Yuan,et al. ERG Rearrangement Is Associated with Prostate Cancer-Related Death in Chinese Prostate Cancer Patients , 2014, PloS one.
[9] G. van der Pluijm,et al. Glycogen synthase kinase-3β inhibition depletes the population of prostate cancer stem/progenitor-like cells and attenuates metastatic growth , 2013, Oncotarget.
[10] H. Hieronymus,et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.
[11] Stine H. Kresse,et al. Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model , 2014, Molecular Cancer.
[12] Chao-yuan Huang,et al. Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients. , 2013, European journal of cancer.
[13] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[14] Peilin Jia,et al. Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers , 2013, Genome Medicine.
[15] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[16] S. Srivastava,et al. Genetic and Molecular Differences in Prostate Carcinogenesis between African American and Caucasian American Men , 2013, International journal of molecular sciences.
[17] A. Sivachenko,et al. Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.
[18] V. Beneš,et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.
[19] S. Ambs,et al. Biological determinants of health disparities in prostate cancer , 2013, Current opinion in oncology.
[20] A. Sivachenko,et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.
[21] S. Srivastava,et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. , 2012, Urology.
[22] Wendy S. W. Wong,et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..
[23] A. Sivachenko,et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.
[24] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[25] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[26] Ken Chen,et al. SomaticSniper: identification of somatic point mutations in whole genome sequencing data , 2012, Bioinform..
[27] Sohrab P. Shah,et al. JointSNVMix: a probabilistic model for accurate detection of somatic mutations in normal/tumour paired next-generation sequencing data , 2012, Bioinform..
[28] S. Hochreiter,et al. cn.MOPS: mixture of Poissons for discovering copy number variations in next-generation sequencing data with a low false discovery rate , 2012, Nucleic acids research.
[29] Tatiana Popova,et al. Supplementary Methods , 2012, Acta Neuropsychiatrica.
[30] J. Downing,et al. High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations. , 2010, Blood.
[31] A. Børresen-Dale,et al. Analyzing cancer samples with SNP arrays. , 2012, Methods in molecular biology.
[32] Wen Tan,et al. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1 , 2011, Nature Genetics.
[33] M. Freedman,et al. The genetics of cancer risk. , 2011, Cancer journal.
[34] Stephen J. Salipante,et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers , 2011, Proceedings of the National Academy of Sciences.
[35] G. Chornokur,et al. Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer , 2011, The Prostate.
[36] M. Rubin,et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.
[37] Eric S. Lander,et al. The genomic complexity of primary human prostate cancer , 2010, Nature.
[38] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[39] D. Berney,et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. , 2010, Cancer research.
[40] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[41] W. Sakr,et al. Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. , 2010, The Journal of urology.
[42] R. Wilson,et al. BreakDancer: An algorithm for high resolution mapping of genomic structural variation , 2009, Nature Methods.
[43] Stine H. Kresse,et al. LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization , 2009, Genes, chromosomes & cancer.
[44] Terence P. Speed,et al. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6 , 2009, Bioinform..
[45] Chen Sun,et al. Delineation of TMPRSS2-ERG Splice Variants in Prostate Cancer , 2008, Clinical Cancer Research.
[46] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2006, Oncogene.
[47] Paulo A. S. Nuin,et al. Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias. , 2006, Cancer Genetics and Cytogenetics.
[48] D. Reich,et al. Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.
[49] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[50] H. Gabra,et al. The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates , 2005, Clinical Cancer Research.
[51] V. Srikantan,et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.
[52] C. Larsson,et al. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. , 2003, Cancer cell.
[53] J. Serth,et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. , 2003, Oncology reports.
[54] S. Kaminskyj,et al. 5' RACE by tailing a general template-switching oligonucleotide. , 2000, BioTechniques.
[55] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[56] R. Harvey,et al. Random-primed cDNA synthesis facilitates the isolation of multiple 5'-cDNA ends by RACE. , 1991, Nucleic acids research.
[57] F. Ramaekers,et al. Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. , 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[58] N. Dubrawsky. Cancer statistics , 1989, CA: a cancer journal for clinicians.
[59] D. Bigner,et al. Patterns of the early, gross chromosomal changes in malignant human gliomas. , 2008, Hereditas.